NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Droid,

Thanks for reposting that again 😶

“PR” for NWBO is substantive and appropriately directed toward the global medical community in the form of independently peer-reviewed publications (as it should be for a pre-commercial clinical-stage biotech awaiting the completion of a very significant regulatory review by the MHRA).

Today, NWBO is on the cusp of initial regulatory approval and the beginning of their commercial-stage status as a company.

Fact ✅: The management are advancing the company toward commercialization every day, and they do provide material updates when appropriate.

The scientific innovation of the novel DCVax-L platform technology is the core foundation of the company’s prospective value, and DCVax-L has been independently peer-reviewed and is currently being reviewed by the MHRA right now. The worldwide IP patent portfolio, DCVax Direct, manufacturing technology, and potential for additional broad range of application of DCVax-L in combination with other technologies for other cancers adds even more to the expansive value potential going forward.

NWBO is advancing each day in all four key areas. Some keys are interconnected too—Oncovir and Roswell could become relevant to more than one of the keys (to name two examples).

Key Determinative Factors:
🔑 Approval(s)
🔑 Capacity to Scale Production Globally
🔑 Partnerships
🔑 Ongoing/Expanding Combo Studies

https://thejns.org/caselessons/downloadpdf/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.pdf

https://www.nature.com/articles/s41467-024-48073-y

https://www.jci.org/articles/view/169314

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847



https://physicianresources.roswellpark.org/news/roswell-park-clinical-trials-offer-novel-immunotherapies-for-advanced/metastatic-tumors-refractory-melanoma

“The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumour microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.

The DC based therapies include versions with tumour antigens loaded into the DCs and versions for intra-tumoural administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The company does not anticipate having to provide any funding or undertake any operational role for these trials.

As previously reported, over time the company has been quietly in-licensing various technologies and IP from various institutions and entities which it believes can be valuable in building a leading franchise in dendritic cell therapies.

The portfolio in-licensed from Roswell Park is complementary to, and builds upon, a portfolio which the company exclusively licensed from another institution last year. Together, the two portfolios encompass more than 20 years of work by one of the foremost groups of dendritic cell experts, led by Dr. Kalinski.

The portfolio in-licensed last year includes the foundational technologies and IP, and positive early-stage clinical trial results, developed by the Kalinski group over 17 years before coming to Roswell. The portfolio in-licensed now includes the further work during the last 7 years at Roswell. Taken together, the company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the company’s own portfolio. The company plans to collaborate with Dr. Kalinski on the further clinical development of the combined technologies.”

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/

https://www.societyns.org/about/officers-detail/linda-m-liau-md-phd-mba-4

https://scitechdaily.com/supercharging-the-immune-system-uclas-pioneering-vaccine-shows-promise-against-deadly-brain-cancer/

https://www.siocapital.com/

https://www.garykmichelson.org/blog/gary-michelson-announces-historic-gift-to-ucla

June 2024

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

February 2024

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html

December 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html

September 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-dr-linda-liau-has-joined-the-companys-scientific-advisory-board-301924864.html

March 2023

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-and-advent-bioservices-announce-receipt-of-license-for-commercial-manufacturing-at-sawston-uk-facility-301776725.html

December 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility-301449083.html

August 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-approval-of-pediatric-investigation-plan-pip-by-mhra-301610850.html

July 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-filing-of-application-for-license-for-commercial-manufacturing-at-sawston-uk-facility-301581737.html

February 2022

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-commencement-of-cancer-vaccine-production-at-its-sawston-uk-facility-301484857.html

September 2020

https://www.prnewswire.com/news-releases/northwest-biotherapeutics-acquires-flaskworks-301122058.html